MAX
Company Analysis Esperion Therapeutics, Inc.
1. Summary
Advantages
- The stock's return over the last year (303.62%) is higher than the sector average (-46.59%).
Disadvantages
- Price (3.43 $) is higher than fair price (2.28 $)
- Dividends (0%) are below the sector average (0.55%).
- Current debt level 86.56% has increased over 5 years from 50.78%.
- The company's current efficiency (ROE=12.27%) is lower than the sector average (ROE=104.5%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| Esperion Therapeutics, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0.9% | -42.5% | -1.5% |
| 90 days | -10.9% | -23.7% | 0.7% |
| 1 year | 303.6% | -46.6% | 13.2% |
ESPR vs Sector: Esperion Therapeutics, Inc. has outperformed the "Healthcare" sector by 350.22% over the past year.
ESPR vs Market: Esperion Therapeutics, Inc. has outperformed the market by 290.43% over the past year.
Stable price: ESPR is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ESPR with weekly volatility of 5.84% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Above fair price: The current price (3.43 $) is higher than the fair price (2.28 $).
Price is higher than fair: The current price (3.43 $) is 33.5% higher than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-7.02) is lower than that of the sector as a whole (33.29).
P/E vs Market: The company's P/E (-7.02) is higher than that of the market as a whole (-108).
5.3. P/BV
P/BV vs Sector: The company's P/BV (-1.04) is lower than that of the sector as a whole (249.13).
P/BV vs Market: The company's P/BV (-1.04) is lower than that of the market as a whole (83.29).
5.5. P/S
P/S vs Sector: The company's P/S indicator (1.21) is lower than that of the sector as a whole (129.32).
P/S vs Market: The company's P/S indicator (1.21) is lower than that of the market as a whole (115.88).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (73.36) is higher than that of the sector as a whole (-27.64).
EV/Ebitda vs Market: The company's EV/Ebitda (73.36) is higher than that of the market as a whole (-92.19).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -16.15% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-16.15%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (241.72%).
6.4. ROE
ROE vs Sector: The company's ROE (12.27%) is lower than that of the sector as a whole (104.5%).
ROE vs Market: The company's ROE (12.27%) is higher than that of the market as a whole (-6.66%).
6.6. ROA
ROA vs Sector: The company's ROA (-18.83%) is lower than that of the sector as a whole (-2.18%).
ROA vs Market: The company's ROA (-18.83%) is lower than that of the market as a whole (37.94%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.04%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.38%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.55%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
9. Insider trades
9.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
9.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 20.01.2026 | Looker Benjamin Officer |
Purchase | 2.88 | 486 | 1 689 |
| 17.12.2025 | Halladay Benjamin Officer |
Purchase | 3.67 | 2 693 | 7 337 |
| 17.12.2025 | Looker Benjamin Officer |
Purchase | 3.67 | 2 392 | 6 517 |
| 17.12.2025 | Koenig Sheldon L. Officer |
Purchase | 3.67 | 17 706 | 48 244 |
| 17.10.2025 | Looker Benjamin Officer |
Purchase | 2.62 | 327 | 1 248 |
Based on sources: porti.ru
